Robotic single site staging in endometrial cancer: A multi-institution study

G. Corrado, L. Mereu, S. Bogliolo, V. Cela, L. Freschi, R. Carlin, B. Gardella, E. Mancini, S. Tateo, A. Spinillo, E. Vizza

Research output: Contribution to journalArticle

Abstract

Objective To evaluate the feasibility and the safety of robotic single site hysterectomy (RSSH) plus or less pelvic lymphadenectomy in FIGO stage I–II endometrial cancer. Materials and methods We prospectively collected patient demographics, operative times, complications, pathologic results, and length of stay on all patients who underwent RSSH plus or less pelvic lymphadenectomy for clinical FIGO stage I or occult stage II endometrial carcinoma. Results From January 2012 to February 2015, 125 patients were included in our study. The median age of the patients was 59 years (range, 35–84 years) and the median body mass index was 27 kg/m2 (range, 19–52 kg/m2). One patient was converted to vaginal surgery due to problems of hypercapnia. The median docking time, console time, and total operative time was 11 min (range, 4–40 min), 80 min (range, 20–240 min) and 122 min (range, 35–282 min), respectively. The median blood loss was 50 ml (range, 10–250 ml). No laparoscopic/laparotomic conversion was registered. Twenty one patients underwent pelvic lymphadenectomy (16.8%) and the median pelvic lymph nodes was 13 (range, 3–32). The median time to discharge was 2 days (range, 1–3 days). No intra-operative complications occurred, while we observed 10 (8%) early post-operative complications. Conclusion RSSH plus or less pelvic lymphadenectomy is technically feasible, safe and reproducible and could be the treatment of choice for patients affected by FIGO stage I–II endometrial cancer. However, randomized controlled trials are needed to confirm these results.

Original languageEnglish
Pages (from-to)1506-1511
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume42
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Robotics
Endometrial Neoplasms
Lymph Node Excision
Hysterectomy
Operative Time
Hypercapnia
Length of Stay
Body Mass Index
Randomized Controlled Trials
Lymph Nodes
Demography
Safety

Keywords

  • Endometrial cancer
  • Minimally invasive surgery
  • Robotic single site hysterectomy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Robotic single site staging in endometrial cancer : A multi-institution study. / Corrado, G.; Mereu, L.; Bogliolo, S.; Cela, V.; Freschi, L.; Carlin, R.; Gardella, B.; Mancini, E.; Tateo, S.; Spinillo, A.; Vizza, E.

In: European Journal of Surgical Oncology, Vol. 42, No. 10, 01.10.2016, p. 1506-1511.

Research output: Contribution to journalArticle

Corrado, G, Mereu, L, Bogliolo, S, Cela, V, Freschi, L, Carlin, R, Gardella, B, Mancini, E, Tateo, S, Spinillo, A & Vizza, E 2016, 'Robotic single site staging in endometrial cancer: A multi-institution study', European Journal of Surgical Oncology, vol. 42, no. 10, pp. 1506-1511. https://doi.org/10.1016/j.ejso.2016.08.014
Corrado, G. ; Mereu, L. ; Bogliolo, S. ; Cela, V. ; Freschi, L. ; Carlin, R. ; Gardella, B. ; Mancini, E. ; Tateo, S. ; Spinillo, A. ; Vizza, E. / Robotic single site staging in endometrial cancer : A multi-institution study. In: European Journal of Surgical Oncology. 2016 ; Vol. 42, No. 10. pp. 1506-1511.
@article{266284c877bb43a3aa7e421e78c8adc4,
title = "Robotic single site staging in endometrial cancer: A multi-institution study",
abstract = "Objective To evaluate the feasibility and the safety of robotic single site hysterectomy (RSSH) plus or less pelvic lymphadenectomy in FIGO stage I–II endometrial cancer. Materials and methods We prospectively collected patient demographics, operative times, complications, pathologic results, and length of stay on all patients who underwent RSSH plus or less pelvic lymphadenectomy for clinical FIGO stage I or occult stage II endometrial carcinoma. Results From January 2012 to February 2015, 125 patients were included in our study. The median age of the patients was 59 years (range, 35–84 years) and the median body mass index was 27 kg/m2 (range, 19–52 kg/m2). One patient was converted to vaginal surgery due to problems of hypercapnia. The median docking time, console time, and total operative time was 11 min (range, 4–40 min), 80 min (range, 20–240 min) and 122 min (range, 35–282 min), respectively. The median blood loss was 50 ml (range, 10–250 ml). No laparoscopic/laparotomic conversion was registered. Twenty one patients underwent pelvic lymphadenectomy (16.8{\%}) and the median pelvic lymph nodes was 13 (range, 3–32). The median time to discharge was 2 days (range, 1–3 days). No intra-operative complications occurred, while we observed 10 (8{\%}) early post-operative complications. Conclusion RSSH plus or less pelvic lymphadenectomy is technically feasible, safe and reproducible and could be the treatment of choice for patients affected by FIGO stage I–II endometrial cancer. However, randomized controlled trials are needed to confirm these results.",
keywords = "Endometrial cancer, Minimally invasive surgery, Robotic single site hysterectomy",
author = "G. Corrado and L. Mereu and S. Bogliolo and V. Cela and L. Freschi and R. Carlin and B. Gardella and E. Mancini and S. Tateo and A. Spinillo and E. Vizza",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.ejso.2016.08.014",
language = "English",
volume = "42",
pages = "1506--1511",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Robotic single site staging in endometrial cancer

T2 - A multi-institution study

AU - Corrado, G.

AU - Mereu, L.

AU - Bogliolo, S.

AU - Cela, V.

AU - Freschi, L.

AU - Carlin, R.

AU - Gardella, B.

AU - Mancini, E.

AU - Tateo, S.

AU - Spinillo, A.

AU - Vizza, E.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Objective To evaluate the feasibility and the safety of robotic single site hysterectomy (RSSH) plus or less pelvic lymphadenectomy in FIGO stage I–II endometrial cancer. Materials and methods We prospectively collected patient demographics, operative times, complications, pathologic results, and length of stay on all patients who underwent RSSH plus or less pelvic lymphadenectomy for clinical FIGO stage I or occult stage II endometrial carcinoma. Results From January 2012 to February 2015, 125 patients were included in our study. The median age of the patients was 59 years (range, 35–84 years) and the median body mass index was 27 kg/m2 (range, 19–52 kg/m2). One patient was converted to vaginal surgery due to problems of hypercapnia. The median docking time, console time, and total operative time was 11 min (range, 4–40 min), 80 min (range, 20–240 min) and 122 min (range, 35–282 min), respectively. The median blood loss was 50 ml (range, 10–250 ml). No laparoscopic/laparotomic conversion was registered. Twenty one patients underwent pelvic lymphadenectomy (16.8%) and the median pelvic lymph nodes was 13 (range, 3–32). The median time to discharge was 2 days (range, 1–3 days). No intra-operative complications occurred, while we observed 10 (8%) early post-operative complications. Conclusion RSSH plus or less pelvic lymphadenectomy is technically feasible, safe and reproducible and could be the treatment of choice for patients affected by FIGO stage I–II endometrial cancer. However, randomized controlled trials are needed to confirm these results.

AB - Objective To evaluate the feasibility and the safety of robotic single site hysterectomy (RSSH) plus or less pelvic lymphadenectomy in FIGO stage I–II endometrial cancer. Materials and methods We prospectively collected patient demographics, operative times, complications, pathologic results, and length of stay on all patients who underwent RSSH plus or less pelvic lymphadenectomy for clinical FIGO stage I or occult stage II endometrial carcinoma. Results From January 2012 to February 2015, 125 patients were included in our study. The median age of the patients was 59 years (range, 35–84 years) and the median body mass index was 27 kg/m2 (range, 19–52 kg/m2). One patient was converted to vaginal surgery due to problems of hypercapnia. The median docking time, console time, and total operative time was 11 min (range, 4–40 min), 80 min (range, 20–240 min) and 122 min (range, 35–282 min), respectively. The median blood loss was 50 ml (range, 10–250 ml). No laparoscopic/laparotomic conversion was registered. Twenty one patients underwent pelvic lymphadenectomy (16.8%) and the median pelvic lymph nodes was 13 (range, 3–32). The median time to discharge was 2 days (range, 1–3 days). No intra-operative complications occurred, while we observed 10 (8%) early post-operative complications. Conclusion RSSH plus or less pelvic lymphadenectomy is technically feasible, safe and reproducible and could be the treatment of choice for patients affected by FIGO stage I–II endometrial cancer. However, randomized controlled trials are needed to confirm these results.

KW - Endometrial cancer

KW - Minimally invasive surgery

KW - Robotic single site hysterectomy

UR - http://www.scopus.com/inward/record.url?scp=84989909015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989909015&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2016.08.014

DO - 10.1016/j.ejso.2016.08.014

M3 - Article

AN - SCOPUS:84989909015

VL - 42

SP - 1506

EP - 1511

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 10

ER -